Bergmann Mie Siewertsen, Loft Nikolai, Schwarz Christopher Willy, Kaur-Knudsen Diljit, Zachariae Claus, Skov Lone
Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
J Dermatol. 2025 Jan;52(1):142-145. doi: 10.1111/1346-8138.17415. Epub 2024 Aug 27.
Whether clinical and genetic markers can be used to differentiate patients with varying responses to different psoriasis therapies needs to be elucidated. Here, we assess whether human leukocyte antigen C (HLA-C)06:02 is associated with response to biologics. Response to treatment was defined as a Psoriasis Area and Severity Index score of ≤2 (PASI≤ 2) after 3 months. In total, 648 patients with psoriasis initiating treatment with biologics were included; 289 were HLA-C06:02 positive and 359 were HLA-C06:02 negative. Patients were treated with tumor necrosis factor (TNF) inhibitors (n = 469), interleukin (IL)-12/23 inhibitors (n = 92), IL-17 inhibitors (n = 78), and IL-23 inhibitors (n = 9). Significantly more patients positive for HLA-C06:02 achieved PASI≤ 2 compared with patients negative for HLA-C06:02 when treated with IL-12/23 inhibitors. There was no significant difference between response in HLA-C06:02 positive and negative patients for TNF inhibitors or IL-17 inhibitors. No analyses were conducted for IL-23 inhibitors because of the limited number of patients. The data confirm that HLA-C*06:02 may be used as a biomarker for response to anti-IL12/23 treatment.
临床和基因标志物能否用于区分对不同银屑病疗法有不同反应的患者，这一问题尚待阐明。在此，我们评估人类白细胞抗原C（HLA-C）06:02是否与生物制剂的反应相关。治疗反应定义为3个月后银屑病面积和严重程度指数评分≤2（PASI≤2）。总共纳入了648例开始使用生物制剂治疗的银屑病患者；其中289例为HLA-C06:02阳性，359例为HLA-C06:02阴性。患者接受肿瘤坏死因子（TNF）抑制剂（n = 469）、白细胞介素（IL）-12/23抑制剂（n = 92）、IL-17抑制剂（n = 78）和IL-23抑制剂（n = 9）治疗。与接受IL-12/23抑制剂治疗时HLA-C06:02阴性的患者相比，HLA-C06:02阳性的患者达到PASI≤2的比例显著更高。对于TNF抑制剂或IL-17抑制剂，HLA-C06:02阳性和阴性患者的反应之间没有显著差异。由于患者数量有限，未对IL-23抑制剂进行分析。数据证实，HLA-C*06:02可作为抗IL12/23治疗反应的生物标志物。
